May. 24 at 11:34 PM
$ALZN In 2025 there were 138 medicines being studies in 182 clinical trials for Alzheimer's. Few have garnered more attention than Lithium in the past year. From the LATTICE study, to publications in the leading medical journals, to online podcast from the some of the most knowledgeable Psychiatrist, lithium carbonate and other lithium salts are being looked at in a different light, mainly because of the Harvard paper in Nature. Why you ask why, well here's the numbers for a new ALZ drug. Based on the event studies on Biogen’s Aducanumab and Lilly’s Donanemab, the value of a drug candidate at or ready for Phase 3 trial would be worth
$20.2 billion to
$20.7 billion, and a Breakthrough Therapy Designation has a value of
$13.4 billion. An Alzheimer’s drug approved by the FDA carries a market value of
$43.4 billion. Having said that, only one company (ALZN) has a patent for a organic lithium salt and it is on the verge of getting delisted due to lack of funding. Gamblers, place your bets.
